CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Diagnostic examination for venous thromboembolismWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (6)

Name (Synonyms) Correlation
D054556 Venous Thromboembolism NIH 0.38
D020246 Venous Thrombosis NIH 0.32
D011655 Pulmonary Embolism NIH 0.32
D004617 Embolism NIH 0.30
D013923 Thromboembolism NIH 0.27
D013927 Thrombosis NIH 0.23

Correlated HPO Terms (3)

Name (Synonyms) Correlation
HP:0002625 Deep venous thrombosis HPO 0.32
HP:0002204 Pulmonary embolism HPO 0.32
HP:0001907 Thromboembolism HPO 0.24

There is one clinical trial.

Clinical Trials

1 Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic

The purpose of this study is to investigate the prevalence of venous thromboembolism in a regional health care system (Region Östergötland, Sweden) before and during the SARS-COV-2 pandemic. In a retrospective observational study, we will review patient data, diagnostic data and treatment data over a three-month period since the onset of the SARS-COV-2 pandemic. This data will be compared with data from the corresponding time frame during the years 2015 to 2019.

NCT04400877 COVID-19 Venous Thromboembolism Pulmonary Embolism Deep Vein Thrombosis SARS-CoV 2 Diagnostic Test: Diagnostic examination for venous thromboembolism
MeSH:Pulmonary Embolism Thrombosis Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis
HPO:Deep venous thrombosis Pulmonary embolism Thromboembolism Venous thrombosis

Primary Outcomes

Measure: Is there an increased prevalence of venous thromboembolism in a regional healthcare system in Sweden during the SARS-CoV-2 pandemic?

Time: March to May in 2020

Measure: Is a SARS-CoV-2-infection an isolated risk factor for thromboembolism?

Time: March to May in 2020

Secondary Outcomes

Measure: Are there geographic differences in the prevalence of venous thromboembolism within the healthcare system?

Time: March to May in 2020

Measure: Is venous thromboembolism associated with increased mortality adjusted for relevant comorbidities?

Time: March to May in 2020

Measure: How long is the time between symptom onset of the SARS-CoV-2-infection and any subsequent venous thromboembolism?

Time: March to May in 2020

Measure: Is treatment with prophylactic antithrombotic or anticoagulant treatment associated with increased survival?

Time: March to May in 2020

Related HPO nodes (Using clinical trials)

HP:0002625: Deep venous thrombosis
Genes 18
HABP2 AKT1 SERPINC1 F9 MTRR SERPIND1 PIEZO1 PMM2 PROS1 PLAT PROC F2 PROC THBD F13A1 F5 SERPINC1 MTHFR
Protein Mutations 3
G20210A G21210A R506Q
SNP 0
HP:0002204: Pulmonary embolism
Genes 43
HABP2 IL23R IL12A SERPINC1 HLA-B CBS ERAP1 KCNJ5 PROS1 SMAD4 GNAQ CCR1 PROC ACVRL1 F2 PROC PTEN SERPINC1 MTHFR KLRC4 ENG CD55 GDF2 AKT1 TET2 PLP1 MEFV C4A IL12A-AS1 MPL AGGF1 UBAC2 TLR4 PROS1 PROC IL10 F13A1 PIGA FAS GNAQ JAK2 PROS1 STAT4
Protein Mutations 2
G20210A G21210A
SNP 0
HP:0001907: Thromboembolism
Genes 27
HABP2 INHBA KCNN4 CYTB KIF20A MTRR CBS F2 FCGR2C SERPINC1 TNNT2 MTHFR KCNQ1 SLC4A1 PRDX1 TNNI3 MYPN ADA2 MMACHC PRKAR1A FLNC F13A1 PIEZO1 JAK2 PIGA EPOR HRG
Protein Mutations 3
G20210A G21210A R506Q
SNP 7
rs10276036 rs1128503 rs1202167 rs1202168 rs1202169 rs2235046 rs4148738
HP:0004936: Venous thrombosis
Genes 99
IL12A CASR FGA PGM1 JAK2 PTEN SERPINC1 PIGM PTH1R GDF2 TET2 IDH1 MEFV IL12A-AS1 CTLA4 PDGFRA IL10 IDH2 THPO GNAQ CPA1 FGG STAT4 SH2B3 KCNN4 IL23R MTRR CBS ERAP1 SAA1 PROS1 SMAD4 PLAT CALR CCR1 MPL ACVRL1 F2 PROC KLRC4 AKT1 CDH23 SPINK1 CTRC AKT1 PTPN22 PROS1 TP53 PROC PRSS1 MPL HBB THBD EPOR PRTN3 CALR PROS1 PRSS2 IDH1 HLA-B SERPIND1 JAK2 PRKAR1A KIF11 PDE4D IDH2 F9 C4A AGGF1 UBAC2 PIEZO1 F13A1 PIEZO1 CFTR HABP2 SERPINC1 GNAQ PROC MPL FGB MTHFR ENG CD55 JAK2 HLA-DPB1 SLC4A1 HLA-DPA1 NOTCH1 MET TET2 MPL TLR4 CTNNB1 PMM2 F5 USP8 FAS TET2 JAK2
Protein Mutations 0
SNP 0